Teriparatide for idiopathic osteoporosis in premenopausal women

A pilot study

Adi Cohen, Emily M. Stein, Robert R. Recker, Joan M. Lappe, David W. Dempster, Hua Zhou, Serge Cremers, Donald J. McMahon, Thomas L. Nickolas, Ralph Müller, Alexander Zwahlen, Polly Young, Julie Stubby, Elizabeth Shane

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Context: Premenopausal women with idiopathic osteoporosis (IOP) have abnormal cortical and trabecular bone microarchitecture. Objective: The purpose of this study was to test the hypotheses that teriparatide increases bone mineral density (BMD) and bone formation and improves trabecular microarchitecture and stiffness in women with IOP. Design: This was an open-label pilot study. Setting: The setting was a tertiary care referral center. Patients: Participants were 21 premenopausal women with unexplained fragility fractures or low BMD. Intervention: Teriparatide was administered at 20 μg daily for 18 to 24 months. Main Outcome Measures: The primary endpoint was within-subject percent change in lumbar spine BMD. Secondary endpoints included percent change in hip and forearm BMD, transiliac biopsy parameters (trabecular bone volume, microarchitecture, stiffness, and adipocytes), serum N-terminal propeptide of procollagen type 1 (P1NP), and C-telopeptide. Results: BMD increased at the spine (10.8 ± 8.3% [SD]), total hip (6.2 ± 5.6%), and femoral neck (7.6 ± 3.4%) (all P <.001). Serum P1NP doubled by 1 month, peaked at 6 months, and returned to baseline by 18 to 24 months. Transiliac biopsies demonstrated significant increases in cortical width and porosity and trabecular bone volume and number increased, mirrored by a 71% increase in trabecular bone stiffness (P <.02-.001). Adipocyte area, perimeter, and volume/marrow volume decreased, with no change in adipocyte number. Four women had no increase in BMD and a blunted, delayed increase in serum P1NP. Nonresponders had markedly lower baseline bone formation rate (0.002 ± 0.001 vs 0.011 ± 0.006 mm2/mm/y; P <.001) and higher serum IGF-1 (208 ± 54 vs 157 ± 44 ng/mL; P = .03). Conclusions: Teriparatide was associated with increased spine and hip BMD and improved trabecular microarchitecture and stiffness at the iliac crest in the majority of women with IOP.

Original languageEnglish
Pages (from-to)1971-1981
Number of pages11
JournalJournal of Clinical Endocrinology and Metabolism
Volume98
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Teriparatide
Bone Density
Osteoporosis
Bone
Minerals
Adipocytes
Pelvic Bones
Spine
Serum
Tertiary Care Centers
Osteogenesis
Stiffness
Biopsy
Porosity
Femur Neck
Collagen Type I
Insulin-Like Growth Factor I
Forearm
Hip
Bone Marrow

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Teriparatide for idiopathic osteoporosis in premenopausal women : A pilot study. / Cohen, Adi; Stein, Emily M.; Recker, Robert R.; Lappe, Joan M.; Dempster, David W.; Zhou, Hua; Cremers, Serge; McMahon, Donald J.; Nickolas, Thomas L.; Müller, Ralph; Zwahlen, Alexander; Young, Polly; Stubby, Julie; Shane, Elizabeth.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 98, No. 5, 05.2013, p. 1971-1981.

Research output: Contribution to journalArticle

Cohen, A, Stein, EM, Recker, RR, Lappe, JM, Dempster, DW, Zhou, H, Cremers, S, McMahon, DJ, Nickolas, TL, Müller, R, Zwahlen, A, Young, P, Stubby, J & Shane, E 2013, 'Teriparatide for idiopathic osteoporosis in premenopausal women: A pilot study', Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 5, pp. 1971-1981. https://doi.org/10.1210/jc.2013-1172
Cohen, Adi ; Stein, Emily M. ; Recker, Robert R. ; Lappe, Joan M. ; Dempster, David W. ; Zhou, Hua ; Cremers, Serge ; McMahon, Donald J. ; Nickolas, Thomas L. ; Müller, Ralph ; Zwahlen, Alexander ; Young, Polly ; Stubby, Julie ; Shane, Elizabeth. / Teriparatide for idiopathic osteoporosis in premenopausal women : A pilot study. In: Journal of Clinical Endocrinology and Metabolism. 2013 ; Vol. 98, No. 5. pp. 1971-1981.
@article{fa779f51af4743e6b955c2bab53dacb2,
title = "Teriparatide for idiopathic osteoporosis in premenopausal women: A pilot study",
abstract = "Context: Premenopausal women with idiopathic osteoporosis (IOP) have abnormal cortical and trabecular bone microarchitecture. Objective: The purpose of this study was to test the hypotheses that teriparatide increases bone mineral density (BMD) and bone formation and improves trabecular microarchitecture and stiffness in women with IOP. Design: This was an open-label pilot study. Setting: The setting was a tertiary care referral center. Patients: Participants were 21 premenopausal women with unexplained fragility fractures or low BMD. Intervention: Teriparatide was administered at 20 μg daily for 18 to 24 months. Main Outcome Measures: The primary endpoint was within-subject percent change in lumbar spine BMD. Secondary endpoints included percent change in hip and forearm BMD, transiliac biopsy parameters (trabecular bone volume, microarchitecture, stiffness, and adipocytes), serum N-terminal propeptide of procollagen type 1 (P1NP), and C-telopeptide. Results: BMD increased at the spine (10.8 ± 8.3{\%} [SD]), total hip (6.2 ± 5.6{\%}), and femoral neck (7.6 ± 3.4{\%}) (all P <.001). Serum P1NP doubled by 1 month, peaked at 6 months, and returned to baseline by 18 to 24 months. Transiliac biopsies demonstrated significant increases in cortical width and porosity and trabecular bone volume and number increased, mirrored by a 71{\%} increase in trabecular bone stiffness (P <.02-.001). Adipocyte area, perimeter, and volume/marrow volume decreased, with no change in adipocyte number. Four women had no increase in BMD and a blunted, delayed increase in serum P1NP. Nonresponders had markedly lower baseline bone formation rate (0.002 ± 0.001 vs 0.011 ± 0.006 mm2/mm/y; P <.001) and higher serum IGF-1 (208 ± 54 vs 157 ± 44 ng/mL; P = .03). Conclusions: Teriparatide was associated with increased spine and hip BMD and improved trabecular microarchitecture and stiffness at the iliac crest in the majority of women with IOP.",
author = "Adi Cohen and Stein, {Emily M.} and Recker, {Robert R.} and Lappe, {Joan M.} and Dempster, {David W.} and Hua Zhou and Serge Cremers and McMahon, {Donald J.} and Nickolas, {Thomas L.} and Ralph M{\"u}ller and Alexander Zwahlen and Polly Young and Julie Stubby and Elizabeth Shane",
year = "2013",
month = "5",
doi = "10.1210/jc.2013-1172",
language = "English",
volume = "98",
pages = "1971--1981",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - Teriparatide for idiopathic osteoporosis in premenopausal women

T2 - A pilot study

AU - Cohen, Adi

AU - Stein, Emily M.

AU - Recker, Robert R.

AU - Lappe, Joan M.

AU - Dempster, David W.

AU - Zhou, Hua

AU - Cremers, Serge

AU - McMahon, Donald J.

AU - Nickolas, Thomas L.

AU - Müller, Ralph

AU - Zwahlen, Alexander

AU - Young, Polly

AU - Stubby, Julie

AU - Shane, Elizabeth

PY - 2013/5

Y1 - 2013/5

N2 - Context: Premenopausal women with idiopathic osteoporosis (IOP) have abnormal cortical and trabecular bone microarchitecture. Objective: The purpose of this study was to test the hypotheses that teriparatide increases bone mineral density (BMD) and bone formation and improves trabecular microarchitecture and stiffness in women with IOP. Design: This was an open-label pilot study. Setting: The setting was a tertiary care referral center. Patients: Participants were 21 premenopausal women with unexplained fragility fractures or low BMD. Intervention: Teriparatide was administered at 20 μg daily for 18 to 24 months. Main Outcome Measures: The primary endpoint was within-subject percent change in lumbar spine BMD. Secondary endpoints included percent change in hip and forearm BMD, transiliac biopsy parameters (trabecular bone volume, microarchitecture, stiffness, and adipocytes), serum N-terminal propeptide of procollagen type 1 (P1NP), and C-telopeptide. Results: BMD increased at the spine (10.8 ± 8.3% [SD]), total hip (6.2 ± 5.6%), and femoral neck (7.6 ± 3.4%) (all P <.001). Serum P1NP doubled by 1 month, peaked at 6 months, and returned to baseline by 18 to 24 months. Transiliac biopsies demonstrated significant increases in cortical width and porosity and trabecular bone volume and number increased, mirrored by a 71% increase in trabecular bone stiffness (P <.02-.001). Adipocyte area, perimeter, and volume/marrow volume decreased, with no change in adipocyte number. Four women had no increase in BMD and a blunted, delayed increase in serum P1NP. Nonresponders had markedly lower baseline bone formation rate (0.002 ± 0.001 vs 0.011 ± 0.006 mm2/mm/y; P <.001) and higher serum IGF-1 (208 ± 54 vs 157 ± 44 ng/mL; P = .03). Conclusions: Teriparatide was associated with increased spine and hip BMD and improved trabecular microarchitecture and stiffness at the iliac crest in the majority of women with IOP.

AB - Context: Premenopausal women with idiopathic osteoporosis (IOP) have abnormal cortical and trabecular bone microarchitecture. Objective: The purpose of this study was to test the hypotheses that teriparatide increases bone mineral density (BMD) and bone formation and improves trabecular microarchitecture and stiffness in women with IOP. Design: This was an open-label pilot study. Setting: The setting was a tertiary care referral center. Patients: Participants were 21 premenopausal women with unexplained fragility fractures or low BMD. Intervention: Teriparatide was administered at 20 μg daily for 18 to 24 months. Main Outcome Measures: The primary endpoint was within-subject percent change in lumbar spine BMD. Secondary endpoints included percent change in hip and forearm BMD, transiliac biopsy parameters (trabecular bone volume, microarchitecture, stiffness, and adipocytes), serum N-terminal propeptide of procollagen type 1 (P1NP), and C-telopeptide. Results: BMD increased at the spine (10.8 ± 8.3% [SD]), total hip (6.2 ± 5.6%), and femoral neck (7.6 ± 3.4%) (all P <.001). Serum P1NP doubled by 1 month, peaked at 6 months, and returned to baseline by 18 to 24 months. Transiliac biopsies demonstrated significant increases in cortical width and porosity and trabecular bone volume and number increased, mirrored by a 71% increase in trabecular bone stiffness (P <.02-.001). Adipocyte area, perimeter, and volume/marrow volume decreased, with no change in adipocyte number. Four women had no increase in BMD and a blunted, delayed increase in serum P1NP. Nonresponders had markedly lower baseline bone formation rate (0.002 ± 0.001 vs 0.011 ± 0.006 mm2/mm/y; P <.001) and higher serum IGF-1 (208 ± 54 vs 157 ± 44 ng/mL; P = .03). Conclusions: Teriparatide was associated with increased spine and hip BMD and improved trabecular microarchitecture and stiffness at the iliac crest in the majority of women with IOP.

UR - http://www.scopus.com/inward/record.url?scp=84877701049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877701049&partnerID=8YFLogxK

U2 - 10.1210/jc.2013-1172

DO - 10.1210/jc.2013-1172

M3 - Article

VL - 98

SP - 1971

EP - 1981

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 5

ER -